HC Wainwright reaffirmed their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a research report report published on Wednesday, Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.
A number of other analysts have also commented on HOWL. Wedbush reaffirmed an outperform rating and issued a $9.00 target price on shares of Werewolf Therapeutics in a research report on Monday, June 3rd. JMP Securities reaffirmed a market outperform rating and set a $12.00 target price on shares of Werewolf Therapeutics in a research report on Tuesday, June 4th.
View Our Latest Research Report on HOWL
Werewolf Therapeutics Stock Performance
Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last announced its earnings results on Friday, May 3rd. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.04). The business had revenue of $0.74 million for the quarter, compared to the consensus estimate of $5.00 million. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.15%. As a group, research analysts forecast that Werewolf Therapeutics will post -1.52 earnings per share for the current year.
Hedge Funds Weigh In On Werewolf Therapeutics
Large investors have recently added to or reduced their stakes in the business. Financial Perspectives Inc raised its stake in shares of Werewolf Therapeutics by 80.0% in the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after purchasing an additional 3,000 shares during the last quarter. Certuity LLC purchased a new stake in Werewolf Therapeutics in the 4th quarter valued at $39,000. Lighthouse Investment Partners LLC bought a new position in Werewolf Therapeutics during the 4th quarter valued at $87,000. Denali Advisors LLC purchased a new position in Werewolf Therapeutics during the 1st quarter worth $172,000. Finally, Acadian Asset Management LLC grew its stake in shares of Werewolf Therapeutics by 119.8% in the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock worth $1,119,000 after acquiring an additional 94,212 shares in the last quarter. Institutional investors own 64.84% of the company’s stock.
Werewolf Therapeutics Company Profile
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Read More
- Five stocks we like better than Werewolf Therapeutics
- 5 discounted opportunities for dividend growth investors
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Investing in Commodities: What Are They? How to Invest in Them
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- Market Cap Calculator: How to Calculate Market Cap
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.